Skip to main content
SpringerLink
Log in

Metastasiertes Lungenkarzinom

Immun-Kombi schlägt Chemotherapie bei NSCLC mit hoher Mutationslast

  • journal club
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Lawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate toPD-1 Inhibition. N Engl J Med. 2017;377(25):2500–01

    Article  PubMed  Google Scholar 

  3. Ramalingam SS, Hellmann MD, Awad MM et al. Tumor mutation burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) nonsmall cell lung cancer (NSCLC): identification of TMB cutoff from Check- Mate 568. Presented at the American Association for Cancer Research 2018 Annual Meeting, Chicago, April 16

  4. Hellmann MD, Rizvi NA, Goldman JW et al. Nivolumab plus ipilimumab as first-line treatment foradvanced non-small-cell lung cancer (Check- Mate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41

Originalie

  • Hellmann MD, Ciuleanu TE, Pluzanski A et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378(22):2093–104

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin IV, Flemmingstraße 2, 09116, Chemnitz, Deutschland

    Stefan Hammerschmidt

Authors
  1. Stefan Hammerschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Hammerschmidt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hammerschmidt, S. Immun-Kombi schlägt Chemotherapie bei NSCLC mit hoher Mutationslast. Pneumo News 10, 21–22 (2018). https://doi.org/10.1007/s15033-018-0977-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-018-0977-9

Search

Navigation